Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roivant Sciences Ltd
(NQ:
ROIV
)
11.94
-0.18 (-1.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Roivant Sciences Ltd
< Previous
1
2
3
4
5
6
Next >
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy
October 24, 2023
The market's dour reaction to Roivant Sciences' latest deal doesn't add up.
Via
The Motley Fool
FSR Stock Alert: What to Know as Fisker Drops Prices
October 23, 2023
Fisker stock is on the move Monday as investors in FSR react to news of a price drop for one version of the company's Ocean EV.
Via
InvestorPlace
PINS Stock Pops as Stifel Upgrades Pinterest
October 23, 2023
Pinterest stock is getting a boost on Monday after a Stifel analyst upgraded PINS to a 'buy' rating and increasing its price target.
Via
InvestorPlace
Why Is Roivant Sciences (ROIV) Stock Up Today?
October 23, 2023
ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates.
Via
InvestorPlace
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
October 23, 2023
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases.
Via
Investor's Business Daily
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal
October 23, 2023
Roche Holding AG (OTC: RHHBY) inked a deal to acquire
Via
Benzinga
What 8 Analyst Ratings Have To Say About Roivant Sciences
October 17, 2023
Via
Benzinga
Analyst Expectations for Roivant Sciences's Future
September 18, 2023
Via
Benzinga
What 9 Analyst Ratings Have To Say About Roivant Sciences
August 31, 2023
Via
Benzinga
Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket
October 23, 2023
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set...
Via
Benzinga
Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session
October 23, 2023
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble.
October 04, 2023
The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck.
Via
Investor's Business Daily
3 No-Brainer Growth Stocks to Buy in October
October 01, 2023
These three top mid-cap stocks could be poised for a long-tailed growth spurt.
Via
The Motley Fool
8 Analysts Have This to Say About Roivant Sciences
August 15, 2023
Via
Benzinga
2 Magnificient Growth Stocks I'm Buying in August
August 02, 2023
These biotech stocks could markedly outperform the broader market.
Via
The Motley Fool
Why Immunovant Stock Is Bolting Higher Today
September 27, 2023
The company may have best-in-class autoimmune disease therapy under its roof.
Via
The Motley Fool
Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday
September 27, 2023
Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market...
Via
Benzinga
Roivant Stock Price Outlook: Strong Pipeline Is A Catalyst
September 27, 2023
Roivant Sciences has 12 drugs in its pipeline. The company’s Immunovant subsidiary reported strong results for its drug. Roivant is in talks with Roche to sell its Chron’s disease for $7 billion.
Via
Talk Markets
Why Shares of Immunovant Are Soaring on Tuesday
September 26, 2023
Immunovant sees strong potential for an autoimmune disorder therapy.
Via
The Motley Fool
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 26, 2023
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi...
Via
Benzinga
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
September 26, 2023
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Autoimmune Disease-Focused Immunovant Stock Trading Higher Today?
September 26, 2023
Immunovant Inc (NASDAQ: IMVT), a unit of Roivant Sciences Ltd (NASDAQ: ROIV), announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in Immunoglobulin G (IgG)...
Via
Benzinga
These 2 Biotech Stocks Are Bucking a Down Market Tuesday
September 26, 2023
Stock index futures pointed to a lower open on Wall Street Tuesday morning.
Via
The Motley Fool
Roivant Sciences: Is Vivek Ramaswamy’s Biotech Stock A Buy?
September 10, 2023
Roivant Sciences stock price has entered a major bull run as investors remain optimistic about the company’s future. The shares surged to a high of $12.67 on Friday, reaching its highest level since...
Via
Talk Markets
Vivek Ramaswamy's Parallels With Warren Buffett Run Deeper Than Wanting To Make Roivant The 'Berkshire Hathaway Of Drug Development'
September 04, 2023
Presidential hopeful Vivek Ramaswamy and Warren Buffett may share different political ideologies but they have at least a couple of things in common.
Via
Benzinga
2 Supercharged Growth Stocks Billionaires Can't Stop Buying
August 28, 2023
A top hedge fund has been steadily buying these two growth stocks in 2023.
Via
The Motley Fool
If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now
August 25, 2023
Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy.
Via
Benzinga
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
August 14, 2023
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease.
Via
Investor's Business Daily
3 Biotech Stocks That Analysts Are Drooling Over
August 07, 2023
With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time.
Via
InvestorPlace
Earnings Scheduled For August 14, 2023
August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.